A detailed history of Cetera Investment Advisers transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 22,297 shares of DNLI stock, worth $466,453. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,297
Previous 11,280 97.67%
Holding current value
$466,453
Previous $261,000 148.66%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$20.96 - $31.05 $230,916 - $342,077
11,017 Added 97.67%
22,297 $649,000
Q2 2024

Aug 22, 2024

BUY
$14.96 - $23.22 $168,748 - $261,921
11,280 New
11,280 $261,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.81B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.